English HTA OKs AbbVie’s Bispecific Antibody Tepkliny for DLBCL After Initial Refusal

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

Patients in England with relapsed or refractory diffuse large B-cell lymphoma will have another treatment option after the health technology appraisal institute NICE recommended AbbVie’s bispecific antibody Tepkinly for funding on the National Health Service . The product is also undergoing a benefit assessment in Germany.

Money and Injection
English HTA decides On AbbVie's subcutaneous bispecific antibody • Source: Shutterstock

NICE, the health technology appraisal (HTA) institute for England and Wales, has recommended AbbVie’s orphan drug Tepkinly (epcoritamab) for treating adults with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) on the National Health Service in England. New data convinced the institute to issue positive final draft guidance after it initially expressed concerns over uncertainties.

“We are delighted that NICE has recognized the benefit that epcoritamab can have on the lives of people living with...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     
    • By Anabel Costa-Ferreira and Ian Schofield

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography